黄色软件免费观看_日本韓國三級國產歐美_在线综合亚洲欧美首页_手机看免费黄色毛片_黄色三级视频_国产 刺激 男女视觉盛宴_在线精品无码字幕无码αv_亚洲香蕉久久国产精品_温客行X周子舒车肉干_日韓歐美一區二區三區免費觀看

Entries by

EISAI RECEIVES LICENSE FOR NEW INDICATION FOR ANTICANCER AGENT KISPLYX? ▼ (LENVATINIB MESYLATE) FOR TREATMENT OF ADVANCED RENAL CELL CARCINOMA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that its European regional headquarters Eisai Europe Ltd. (Location: U.K.) has received license from the European Commission for anticancer agent Kisplyx? ▼ (generic name: lenvatinib mesylate, “l(fā)envatinib”) in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy. Following the United States, Europe marks the second region where lenvatinib has been licensed for the advanced renal cell carcinoma indication.

2016/9/15 by

EISAI SELECTED FOR FOURTH CONSECUTIVE YEAR OF MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2016

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been selected for a fourth consecutive year of membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI).

2016/9/14 by

U.S. FDA CONFIRMS SUFFICIENT DATA TO ADVANCE INVESTIGATIONAL BACE INHIBITOR E2609 FOR TREATMENT OF EARLY ALZHEIMER’S DISEASE TO PHASE III PLANNING UNDERWAY TOWARDS PHASE III STUDY INITIATION IN FY2016

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that, at its recent meeting with the U.S. Food and Drug Administration (FDA), the FDA confirmed there was sufficient data to support the advancement of its novel investigational oral beta-secretase cleaving enzyme (BACE) inhibitor E2609 into Phase III clinical studies. E2609 was discovered by Eisai and is being jointly developed by Eisai and Biogen Inc. (Headquarters: Massachusetts, United States, CEO: George A. Scangos, “Biogen”) for early Alzheimer’s disease.

2016/8/9 by

EISAI RECEIVES POSITIVE CHMP OPINION ON NEW INDICATION FOR ANTICANCER AGENT LENVATINIB IN COMBINATION WITH EVEROLIMUS FOR TREATMENT OF ADVANCED RENAL CELL CARCINOMA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its European regional headquarters Eisai Europe Ltd. (Location: U.K.) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on anticancer agent lenvatinib mesylate (generic name, “l(fā)envatinib”) in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF) targeted therapy. If approved, lenvatinib will be launched under the brand name Kisplyx??for this indication.

2016/7/22 by

ANTIOBESITY AGENT VENESPRI? (LORCASERIN) APPROVED IN MEXICO – FIRST COUNTRY IN LATIN AMERICA TO APPROVE LORCASERIN

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its pharmaceutical sales subsidiary in Mexico, Eisai Laboratorios, S. de R.L. de C.V. (Location: Mexico City, “Eisai Mexico”) has received approval for the antiobesity agent VENESPRI? (lorcaserin hydrochloride, U.S. brand name: BELVIQ?, “l(fā)orcaserin”) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2?or greater (obese) or 27 kg/m2?or greater (overweight) in the presence of at least one weight-related co-morbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes) by the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS), the Mexico regulatory authority. Mexico marks the first country in Latin America where lorcaserin is approved. Lorcaserin will be marketed in Mexico under the brand name VENESPRI.

2016/7/15 by

Eisai China, Trip to Guizhou – Record on Guizhou Green Expo, Big Health & Pharmaceutical Industry Fair and Summit

Eco Forum Global Annual Conference Guiyang 2016, Guizhou Green Expo-Big Health & Pharmaceutical Industry Fair and Summit has been held successfully in July 8-10, 2016 in Guiyang City, Guizhou Province. Chairman Mr. Norio Kaneko and General Manager Ms. Yanhui Feng of Eisai (China) Holding Co., Ltd and Eisai China Inc. are invited to attend the Forum and Expo. Eisai China Inc. and Eisai (Liaoning) Pharmaceutical Co., Ltd equip with special show-booths at the Expo.

2016/7/11 by

Eisai China participated in the 2nd Annual Scientific Session of Chinese Stroke Association (CSA) and Tiantan International Stroke Conference (TISC) — Focus on Post-Stroke Cognitive Impairment (PSCI)

The 2nd Annual Scientific Session of Chinese Stroke Association (CSA) and Tiantan?International Stroke Conference (TISC)?were?held at Beijing National Convention Center?in Beijing on June 24-26, 2016. And medical doctors and experts visited Eisai China Inc. (Eisai China)’s booth area continuously which received a great attention.?

2016/6/27 by